Tesamorelin

Tesamorelin — FDA-Approved GHRH Analogue by Dragon Pharma

Tesamorelin is Dragon Pharma's formulation of the FDA-approved GHRH analogue Tesamorelin at 5mg per vial — the only peptide in the GH secretagogue class with Phase III randomised controlled trial data specifically demonstrating visceral fat reduction. Approved under the trade name "Egrifta" (Theratechnologies, 2010), Tesamorelin is structurally a modified full-length GHRH(1-44) with enhanced metabolic stability.

Also searched as: Tesamorelin 5mg, Egrifta equivalent, GHRH analogue fat loss, Tesamorelin Dragon Pharma, GHRH visceral fat.

What Makes Tesamorelin Structurally Different From Natural GHRH

Unlike Sermorelin (GHRH 1-29) which is a truncated fragment, Tesamorelin preserves the full 44 amino acid sequence of native GHRH but adds a chemical modification that is rarely explained in competitor content:

• Tesamorelin is GHRH(1-44) with a trans-3-hexenoic acid group conjugated to the N-terminal tyrosine residue
• This modification serves one primary purpose: resistance to DPP-IV (dipeptidyl peptidase IV) — the enzyme that rapidly degrades native GHRH
• Native GHRH has a half-life of approximately 7 minutes in vivo due to DPP-IV degradation. Tesamorelin's trans-3-hexenoic acid modification extends this to approximately 26 minutes — modest compared to CJC-1295 DAC's 6-8 days, but sufficient to allow meaningful daily subcutaneous dosing
• Because Tesamorelin preserves the full 44 amino acid sequence (unlike Sermorelin at 1-29 or CJC-1295 modifications at specific positions), it maintains the most complete GHRH receptor interaction of any synthetic analogue — contributing to its potent and consistent GH stimulation in clinical trials

The Clinical Data — What Phase III Trials Actually Showed

Tesamorelin's clinical evidence is more extensive than any other GH secretagogue in this category, and the specific numbers are rarely presented clearly:

The Visceral vs Subcutaneous Fat Distinction — The Critical Information Gap

One of the most important and least-explained facts about Tesamorelin — and a finding that significantly affects how it should be used:

• Tesamorelin selectively reduces visceral adipose tissue (VAT) — the fat stored deep in the abdominal cavity around internal organs
• Subcutaneous fat (the fat under the skin) did not change significantly from placebo in Phase III trials
• This distinction matters because: visceral fat is metabolically active and associated with insulin resistance, cardiovascular risk and the "pot belly" appearance. Subcutaneous fat is the fat you can pinch — body-weight scales measure both types together
• Practical implication: users may see body weight change minimally while waist circumference and abdominal definition improve — because VAT is being reduced while subcutaneous fat remains unchanged
• This also means Tesamorelin is not a general fat loss compound — it is specifically targeted at visceral fat depot reduction

Effects and Benefits

• Visceral adipose tissue reduction of approximately 15% over 26 weeks at 2mg/day — Phase III RCT confirmed
• Hepatic (liver) fat reduction of approximately 31% over 12 months
• IGF-1 elevation of 60-70% above baseline — supporting body recomposition alongside fat loss
• Improved waist circumference — mean reduction of 2.6cm over 26 weeks vs placebo
• No suppression of natural testosterone — does not require Post Cycle Therapy
• Pulsatile GH pattern preserved — daily dosing maintains physiological GH rhythmicity

Dosage and Administration

At 5mg per vial, the clinical dose of 2mg/day provides 2.5 days per vial — approximately 1 vial every 2-3 days for a full 26-week protocol. This makes Tesamorelin the highest vial consumption rate of any Dragon Pharma peptide by volume at full clinical dosing. Combine with Ipamorelin for synergistic GHRH + GHRP GH pulse amplification, or use the Ipamorelin + Tesamorelin blend for convenience.